FDA Misbranding Action Clarification Sought By WLF In Appeals Brief
This article was originally published in The Gray Sheet
Executive Summary
FDA should not be allowed to pursue a misbranding action based solely on the dissemination of information that complies with the district court's injunction in Washington Legal Foundation v. Henney permitting manufacturer-sponsored dissemination of peer-reviewed journal articles and medical texts, WLF argues in its Nov. 8 appellate brief.